Comparative pharmacokinetics of theophylline in rabbits and in humans with hyperlipidemia

Pulmonary Pharmacology

Volumn 9, Issue 3, 1996, Pages 175-178

  Wojcicki J ^a   Gornik W ^a   Pawlik, A ^a   Drozdzik M ^a   Gawronska Szklarz B ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Humans; Hyperlipidemia; Pharmacokinetics; Rabbits; Theophylline

Indexed keywords

AMINOPHYLLINE; THEOPHYLLINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HYPERLIPIDEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0030174984     PISSN: 09520600     EISSN: None     Source Type: Journal    
DOI: 10.1006/pulp.1996.0020     Document Type: Article

References (19)

1. 1. Aleksandrow D, Michajlik A, Bartnikowska E. Lipids in the blood of neonates and mothers - an attempt of early detection on primary hiperlipidemias (in Polish). Pol Tyg Lek 1975; 30: 5-8.
2. 2. Cendella R J, Croutchamel W G, Bierkamper G C, Westfall D P. Alteration of drug pharmacodynamics by hiperlipidemia. Arch Int Pharmacodyn Ther 1975; 218: 299-311.
3. 3. Gawrońska-Szklarz B, Kalinowski W, Wójcicki J. The influence of hyperlipidemia and its treatment on pharmacokinetics of tetracycline (in Polish). Pol Tyg Lek 1984; 39: 295-298.
4. 4. Wójcicki J, Kalinowski W, Gawrońska-Szklarz B. Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. Arzneim-Forsch 1985; 35: 991-993.
5. 5. Cheymol G. Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 1988; 2: 239-256.
6. 6. Christoff P, Conti G, Naylon C. Procainamide disposition in obesity. Drug Intell Clin Pharm 1983; 17: 516-522.
7. 7. Piafsky K M, Sitar D S, Rangno R E, Ogilvie R J. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977; 296: 1495-1497.
8. 8. Kriegelstein J, Meffert A, Niemeyer D. Influence of emulsified fat on chloropromazine availability in rabbit blood. Experientia 1974; 30: 924-926.
9. 9. Bierman C W, Williams P V. Therapeutic monitoring of theophylline. Rationale and current status. Clin Pharmacokinet 1989; 17: 377-384.
10. 10. Pancorbo S, Sawchuk R J, Dashe Ch, Schallock M. Use of a pharmacokinetic model for individualizing intravenous doses of aminophylline. Eur J Clin Pharmacol 1979; 16: 251-245.
11. 11. Celardo A, Traina G L, Jankowski A, Bonati M. Pharmacokinetics of theophylline and its metabolites in rabbits. Eur J Drug Metab Pharmacokin 1985; 10: 279-288.
12. 12. Bickel M H. The role of adipose tissue in the distribution and storage of drugs. Prog Drug Res 1984; 28: 273-303.
13. 13. Edwards D J, Zarowitz B J, Slaughter R L. Theophylline. In Evans W E, Shentag J J, Jusko W J, eds. Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. Vancouver: Applied Therapeutics Inc, 1992, pp 10-13.
14. 14. Frederiksen M C, Ih-Ruo T, Chow M J, Antkinson A J. Theophylline pharmacokinetics in pregnancy. Clin Pharmacol Ther 1986; 3: 321-328.
15. 15. Rowland M. Protein binding and drug clearance. Clin Pharmacokin 1984; 9 (Suppl. 1): 10-17.
16. 16. Scheife R. Protein binding; what does it mean? Ann Pharmacother 1989; 23: 527-531.
17. 17. Shaw L M, Fields L, Mayock R. Factors influencing theophylline serum protein binding. Clin Pharmacol Ther 1982; 32: 490-496.
18. 18. Vestal R E, Thummel K F, Mercer G D, Koup J R. Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes. Eur J Clin Pharmacol 1986; 30: 113-120.
19. 19. Spector A A, Santos E C. Influence of free fatty acid concentration on drug binding to plasma albumin. Ann N Acad Sci 1973; 226: 247-258.